Home    About Us    Medic-All    Bio B2B    Hot Topic     Expo     Login | Join Now     
Bio B2BTLC, Ltd. 〉TLC599

TLC599

TLC599

TLC599 is a sustained release therapy for the treatment of osteoarthritis pain. TLC's lipid-based technology allows the use of the corticosteroid dexamethasone in a new formulation that is both fast onset and sustained duration.

Request for Collaboration
Overview
TLC599 is our proprietary BioSeizer formulation of dexamethasone  sodium phosphate (DSP) designed to provide sustained pain management over an extended period of three months or more. TLC599 has the potential to enable patients to receive both immediate and sustained benefit from the local delivery of a highly potent and clinically validated steroid that typically has a very short half-life. Our clinical data suggests that we may be able to achieve a best-in-class duration of action for an intraarticular steroid. 
Application
Osteoarthritis pain
Advantages:
  • Encapsulated with the sustained release platform "BioSeizer", phase 1/2 results showed sustained and significant pain control effect at week 12, the end of the observation period
  • Phase 1/2 data showed no severe adverse effect in terms of safety profile
People who like this also like
  • Preimplantation Genetic DiagnosisPreimplantation Genetic Diagnosis
  • HPAPI manufacturingHPAPI manufacturing
  • Products PipelineProducts Pipeline
  • Taigexyn®  (Nemonoxacin)Taigexyn® (Nemonoxacin)
  • New Project ManagementNew Project Management
  • Good Agriculture Practice Cultivation PlatformGood Agriculture Practice Cultivation Platform
  • Glycan arrays and glycoprobesGlycan arrays and glycoprobes
  • TLC399TLC399
  • CVM-1118CVM-1118
  • Lead discoveryLead discovery